

Variable	First chronic phase		Advanced phase	
	N eval	N (%)	N eval	N (%)
Supplemental form				
Best imatinib response prior to transplant	176		216	
None		18 (10)		34 (16)
Hematological		61 (35)		84 (39)
Cytogenetic >35% Ph+ metaphases		45 (26)		46 (21)
Cytogenetic <35% Ph+ metaphases		36 (20)		39 (18)
Molecular		16 (9)		13 (6)
Imatinib maximum dose (mg/day), median (range)	167	400 (150-800)	200	600 (200-999)
Imatinib maximum dose (mg/day):categories	185		224	
0-399		88 (48)		43 (19)
400-600		50 (27)		95 (42)
>600		29 (15)		62 (28)
Unknown		18 (10)		24 (11)
Duration of imatinib therapy, median months (range)	174	9 (0.2-55)	213	8 (1-60)
Interval from last dose imatinib to transplant, months	185		224	
0-½		94 (51)		117 (52)
½-1		21 (11)		17 (8)
1-3		25 (13)		37 (16)
3-6		16 (9)		31 (14)
6-12		10 (5)		6 (3)
>12		3 (2)		3 (1)
unknown		16 (9)		13 (6)
Reasons to proceed to HCT	180		222	
Planned transplant		97 (54)		95 (43)
Intolerance to imatinib		17 (9)		13 (6)
Imatinib therapy failure or no response		66 (37)		114 (51)
If imatinib therapy failure or no response	66		114	
Unsatisfactory/no response		30 (45)		11 (10)
Hematologic progression		9 (14)		71 (62)
Cytogenetic progression		21 (32)		17 (15)
Molecular progression		2 (3)		2 (2)
Unspecified		4 (6)		13 (11)

Abbreviations: CIBMTR = Center for International Blood and Marrow Transplant Research; Ph+ = Philadelphia chromosome positive; HCT = hematopoietic cell transplantation